Surmodics (SRDX)
(Real Time Quote from BATS)
$25.92 USD
-0.25 (-0.96%)
Updated Apr 29, 2024 03:22 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRDX 25.92 -0.25(-0.96%)
Will SRDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SRDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRDX
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
SRDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neogen (NEOG) Q3 Earnings and Revenues Lag Estimates
New Strong Buy Stocks for April 9th
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
Other News for SRDX
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)
Surmodics to Participate in Upcoming Investor Conferences in March and April
Surmodics Shareholders Approve Directors and Fiscal Oversight